Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression

Key Points

• The aim is to evaluate gilteritinib's ability to overcome second-generation TKI resistance in ALK-rearranged non-small-cell lung cancer (NSCLC).
• In vitro assessments of H2228/Al cell growth and apoptosis induction using gilteritinib.
• Co-culture and rescue experiments to explore mechanisms of action.
• Animal experiments to validate findings of PD-L1 and CD8 co-expression inhibition.
• Gilteritinib significantly inhibited cell growth and induced apoptosis in H2228/Al cells.
• It effectively reduced ALK protein levels in the cells tested.
• Gilteritinib overcame alectinib resistance by inhibiting PD-L1 and CD8 co-expression.

Abstract